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The spinal muscular atrophy (SMA) protein, survival
motor neuron (SMN), functions in the biogenesis of
small nuclear ribonucleoproteins (snRNPs). SMN
has also been implicated in tissue-specific functions;
however, it remains unclear which of these is impor-
tant for the etiology of SMA. Smn null mutants
display larval lethality and show significant locomo-
tion defects as well as reductions in minor-class spli-
ceosomal snRNAs. Despite these reductions, we
found no appreciable defects in the splicing of
mRNAs containing minor-class introns. Transgenic
expression of low levels of either wild-type or an
SMA patient-derived form of SMN rescued the larval
lethality and locomotor defects; however, snRNA
levels were not restored. Thus, the snRNP biogen-
esis function of SMN is not a major contributor to
the phenotype of Smn null mutants. These findings
have major implications for SMA etiology because
they show that SMN’s role in snRNP biogenesis can
be uncoupled from the organismal viability and loco-
motor defects.
INTRODUCTION
Spinal muscular atrophy (SMA) is caused by recessive loss-of-
functionmutations in the survivalmotorneuron1 (SMN1) gene (Le-
febvre et al., 1995). The disease is characterized bymotor neuron
loss, atrophy of the proximal muscles, and progressive symmet-
rical paralysis. SMA symptoms vary in severity and are classified
by types I to IV, ranked in decreasing order (Ogino and Wilson,
2004). In the most severe form (SMA type I), which is also the
most common, death usually occurs by two years of age.
SMN is the central component of a multimeric protein assem-
blage known as the SMN complex (Burghes and Beattie, 2009).
The best-characterized function of this complex is in the biogen-
esis of small nuclear ribonucleoproteins (snRNPs), primary
components of the spliceosome. The SMN complex chaperones624 Cell Reports 1, 624–631, June 28, 2012 ª2012 The Authorsassembly of Sm proteins onto spliceosomal snRNAs (Meister
et al., 2001; Pellizzoni et al., 2002). Complete loss of SMN is
lethal in all organisms investigated to date. SMA, therefore, is
a disease that arises because of a reduction in SMN levels, not
a complete loss. Humans have two paralogs of SMN, named
SMN1 and SMN2, both of which contribute to total cellular levels
of SMN protein. SMN2, however, contains a base change that
primarily leads to production of a truncated, unstable protein
product. Current estimates suggest that SMN2 produces only
10%–15% of the level of full-length protein produced by SMN1
(Lorson et al., 2010). Although this amount is not enough to
completely compensate for loss of SMN1, SMN2 is sufficient
to rescue embryonic lethality.
A causative link betweenSMN1 andSMAwas establishedover
15 years ago; however, the mechanism of disease pathology
remains unclear. In addition to roles in snRNP biogenesis, SMN
has been implicated in a number of tissue-specific processes,
including axonal pathfinding (McWhorter et al., 2003; Sharma
et al., 2005), axonal transport of b-actin mRNP (Rossoll et al.,
2003), neuromuscular junction formation and function (Chan
et al., 2003; Kariya et al., 2008; Murray et al., 2008; Kong et al.,
2009), myoblast fusion (Shafey et al., 2005), and maintenance
of muscle architecture (Rajendra et al., 2007; Walker et al.,
2008; Bowerman et al., 2009). Thus, it is not surprising that
therapeutic approaches targeting SMA are primarily focused
on increasing production of full-length SMN protein from the
SMN2 gene in patients (Lorson et al., 2010). Although these
approaches are extremely important, it is clear that a deeper
understanding of the molecular etiology of SMA will be essential
to develop effective treatments and minimize side effects.
Here, we present a Drosophila model system to study SMA
patient-derived loss-of-function mutations in the background
of an Smn null allele. Smn null mutants display a reduction in
the levels of a subset of snRNAs and considerable defects in
larval locomotion. Transgenic expression of FLAG-tagged wild-
type (WT) dSMN rescues larval locomotion and organismal
viability but, surprisingly, fails to rescue snRNA levels. Expres-
sion of an SmnT205I construct (which mimics SMNT274I in
humans) also rescues the larval motility and viability defects,
but the majority of these animals die as pupae with an snRNA
profile similar to that of the wild-type transgenics. These data
Figure 1. Characterization of Smn Null Flies
(A) Smn/ mutants begin dying 4 days post-egg-laying (DPE), with a number
of larvae surviving for extended periods without pupariation. Note that by
6 DPE the OR control larvae had all pupated. For each genotype n R 100
larvae, collected on day 1 post-egg-laying.
(B) Developmental western blot of dSMN levels in control (OR) and Smn null
animals.
(C) Developmental northern blot showing major and minor class spliceosomal
snRNA levels in OR and Smn null larvae. 7SK and U6 snRNA are shown as
loading controls. These snRNA levels are reflective of the total snRNP levels,
as shown in Figure S1. An asterisk marks a heteroallelic variant U11 snRNA
present in the Smn null background (see Figure S1).show that the observed decreases in snRNA levels in Smn null
animals are not major contributors to organismal phenotype
and indicate that non-snRNP biogenesis functions of SMN play
important roles in SMA pathology.RESULTS AND DISCUSSION
Characterization of Smn Null Flies
In order to minimize genetic background effects arising from
recessive second-site mutations, we used flies bearing two
different Smn null alleles for phenotypic characterization.
SmnD/+ flies (Rajendra et al., 2007) were crossed with SmnX7/+
(Chang et al., 2008) to produce SmnD/X7 trans-heterozygous
mutants, herein referred to as Smn/. Smn/ larvae begin to
die in early third instar,80 hr (day 4) post-egg-laying (Figure 1A).
The primary lethal phase continues through day 5, after which
time the number of larvae reduces gradually. Consistent with
previous observations (Shpargel et al., 2009), 20%–30% of
Smn null larvae are ‘‘long lived’’ and can survive for many days
without undergoing metamorphosis or exhibiting the wandering
behavior typical of the late third instar. Larval dSMN levels are
highest at 1 day post-egg-laying (DPE) and then decrease and
remain constant. In Smn/ mutants, dSMN levels are already
reduced on day 1 and are almost undetectable by 2 DPE (Fig-
ure 1B). Thus, a significant fraction of animals are able to survive
for long periods with very low levels of dSMN.
To determine whether a correlation exists between dSMN and
snRNA levels, developmentally staged Smn/ and Oregon-R
(OR) larvae were harvested and split into two groups of 20–
50 animals. One group was used to extract protein for western
analysis and the other for RNA extraction and northern blotting
(Figure 1C). The snRNA levels in both OR and Smn null flies
were greatest on day 1, after which time they decreased and re-
mained constant throughout larval development. This was
a surprising finding in the mutant larvae because dSMN levels
are severely reduced by 2 DPE, yet no dramatic or progressive
reduction in snRNA levels was observed. We did note a slight
decrease in U1, U5, and U11 snRNAs in the mutants and
a greater decrease in levels of U12 and U4atac snRNAs (Fig-
ure 1C). These findings are consistent with observations in the
mammalian system that minor-class snRNAs (particularly
U4atac and U12) are more sensitive to SMN depletion (Gaba-
nella et al., 2007; Workman et al., 2009). We also note that levels
of U6atac appear to be upregulated in the Smn/ larvae,
although the molecular basis for this is currently unknown. We
did not detect an increase in unassembled snRNAs in mutant
larvae, as shown by coimmunoprecipitation with anti-Sm anti-
body, Y12 (Figure S1). Thus, as observed in mammalian cell
culture systems (Sauterer et al., 1988), total Drosophila snRNA
levels reflect total snRNP levels.
The observed decrease in U4atac and U12 snRNAs in Smn
null larvae was neither exacerbated by prolonged reduction of
dSMN nor did it result in appreciable defects in the splicing of
minor-class (U12-type) introns. Real-time quantitative reverse
transcription polymerase chain reaction (qRT-PCR) analysis
was performed using RNA from Smn/ and wild-type larvae.
Relative levels of spliced mRNAs from genes that contain U12-
type introns were measured (Figure 2). Hypomorphic U6atac
larvae (U6atac/), which are known to be defective in U12-
dependent splicing (Otake et al., 2002; Pessa et al., 2010),
were used as positive controls. As shown in Figure 2, mRNAs
from these genes were significantly reduced in U6atac mutants,
whereas they were largely unaffected in Smn mutants.Cell Reports 1, 624–631, June 28, 2012 ª2012 The Authors 625
Figure 2. Analysis of Minor-Class Intron Splicing Defects in Smn Null Mutants and U6atac Hypomorphs
mRNA levels for 18 genes containing putative U12-dependent introns in76 hr OR, Smn/, and U6atac/ larvae were measured by qRT-PCR and normalized
to OR using Rpl32 mRNA. Samples were run in technical triplicates for each of three biological replicates. The error bars indicate standard error of the mean.
Primers were designed to cross the exon junction flanking the U12-type intron such that only spliced mRNAs would be detected (inset). The U6atac/ larvae
showed robust defects in splicing of these introns (avg. = 0.32). Nine of the 18mRNAs were reduced inU6atac/ animals with p values < 0.01, eight had p < 0.05,
and the levels of onemRNA approached, but did not reach, significance (CG7892, p0.08). In contrast, splicing of these same introns was relatively unaffected in
Smn/ animals (avg. = 1.06). Although a majority of the mRNAs were not affected, we note that the four mRNAs showing the greatest decrease in the Smn/
mutants were also the most severely affected mRNAs in U6atac/mutants. Each of these (CG18177, CG33108, CG15081, and CG11839) had p values < 0.05,
although none were below 0.01.Transgenic Expression of an SMA Patient-Derived
Mutation in dSMN Rescues Smn/ Larval Lethality
Although analysis of Smn null mutants is informative, the many
putative functions of SMN make it difficult to parse out the
precise cause of lethality. We thus wanted to developDrosophila
SMA models that perturb only a subset of SMN functions rather
than affecting all of them. As a proof of principle, we created flies
expressing an SMA patient-derived point mutation, T205I. This
mutation corresponds to an SMA type II/III mutation, T274I,
located in the YG box domain of SMN (Sun et al., 2005). We
generated transgenic flies carrying either a wild-type or T205I
mutant transgene, inserted at site 86Fb on chromosome 3 (Bis-
chof et al., 2007). To preserve endogenous expression patterns,
constructs are driven by the native Smn promoter and contain
native 30 and 50 flanking sequences. Transgenic proteins can
be distinguished from the endogenous by the presence of an
N-terminal 3X FLAG tag.
Expression of the wild-type construct (SmnWT) in the Smn/
background results in >70% rescue of lethality (Figure 3A). The
surviving adults are fertile, with no apparent defects in flight or
motility. Similarly, expression of the SmnT205I construct fully
rescues larval lethality of the null mutant. And, whereas 25%
of SmnT205I mutants eclose as adults, the majority of these626 Cell Reports 1, 624–631, June 28, 2012 ª2012 The Authorsanimals die as pupae (Figure 3A). This partial rescue of the null
phenotype is consistent with the human SMNT274I mutation,
which causes a relatively mild form of SMA (Sun et al., 2005).
Note that both the WT and T205I rescue animals show some
developmental delay because they pupate and eclose a day later
than OR controls.
SmnT205I Is Moderately Defective in Self-Oligmerization
A number of human SMA-derivedmutations in the YGbox region
of SMN, including SMNT274I, have been shown to be defective in
oligomerization (Lorson et al., 1998). We tested a panel of dSMN
proteins, including T205I, for similar defects. FLAG- and Myc-
tagged versions of each construct were expressed in Drosophila
S2 cells and coimmunoprecipitation profiles compared. Immu-
noprecipitation was performed with anti-FLAG antibody, and
the amount of Myc-tagged protein that coprecipitated was
measured. As shown in Figure 3B, the amount of Myc-
dSMN(T205I) precipitated by FLAG-dSMN(T205I) was reduced
compared to the amount of Myc-dSMN(WT) precipitated by
FLAG-dSMN(WT), indicating a deficiency in its ability to self-
oligomerize. This conservation between the human and fly
SMN mutants also extends to other SMA-derived point muta-
tions. Both SmnG206S (corresponding to human SMNG275S) and
Figure 3. Transgenic Rescue of Smn Null Animals with an SMA Patient-Derived Point Mutation, T205I
(A) Analysis of Smn null flies expressing SmnWT and SmnT205I transgenic constructs. Approximately 100 first instar larvae were collected, and the fraction of live
animals at subsequent developmental stages was measured.
(B) dSMN(T205I) showsmild oligomerization defects. Lysates from cells coexpressing FLAG- andMyc-tagged versions of each dSMN point mutant andWTwere
immunoprecipitated with anti-FLAG antibody followed by western with anti-Myc antibody.
(C) Western blot of lysates from SmnWT and SmnT205I larvae and pupae probed with anti-dSMN. Tubulin was used as loading control.
(D) Western analysis of lysates from flies heterozygous for the native and Actin5C promoter-driven FLAG-Smn constructs. Blots probed with anti-dSMN; anti-
tubulin as control.
(E) SmnWT and SmnT205I animals rescued locomotion defects present in Smn/ larvae. Graph shows the performance of Smn/, SmnWT, and SmnT205I larvae
compared to OR in the righting assay. At least 18 larvae were measured for each genotype, and Student’s t test was used to calculate p values. *p < 0.05;
**p < 0.01; ***p < 0.0001.
(F) Graph illustrating results of the burrowing assay for OR, Smn/, SmnWT, and SmnT205I larvae. A chi-square test was performed to determine significance. All
error bars represent the standard error of the mean.SmnY203C (SMNY272C) mutants were defective in oligomerization,
similar to reports of their human counterparts (Lorson et al.,
1998). Furthermore, the severity of these defects is also
conserved, as Y203C was less effective at binding to itself
than either T205I or G206S (Figure 3D). Likewise, Y272C has
a more severe oligomerization defect than T274I (Lorson et al.,
1998). Thus, T205I displays a relatively mild defect in self-
oligomerization.
SMN molecules that are unable to oligomerize are unstable
(Burnett et al., 2009). Thus, we expected that T205I transgenicflies might display reduced levels of FLAG-dSMN compared to
transgenic flies expressing WT FLAG-dSMN. However, levels of
FLAG-dSMN in both the WT and T205I transgenic lines were
equivalent, as analyzed by western blotting (Figure 3C). This
finding indicates that the mild defect in T205I oligomerization
does not significantly affect dSMN levels. In addition, this
suggests that the lethality of the T205I mutant is not due to insuf-
ficientprotein levelsbut ratherdue toamolecular defect in dSMN.
As shown in Figure 3C, expression of both transgenic FLAG-
dSMN constructs (WT and T205I) was significantly below theCell Reports 1, 624–631, June 28, 2012 ª2012 The Authors 627
Figure 4. SmnWT and SmnT205I Animals Have Similar snRNA Profiles
(A) Northern blot showing levels of major andminor class snRNAs in76 hr larvae fromOR, Smn/, SmnWT, and SmnT205I lines. U6 snRNAwas used as a control
for loading.
(B) Graph illustrating the relative levels of snRNAs in Smn/, SmnWT, and SmnT205I larvae compared to OR. Northern blots from at least four biological replicates
were used to quantify snRNA levels, using U6 for normalization. Student’s t test was used for statistical analysis. Error bars represent the standard error of the
mean. See Figure S2 for additional information.level of endogenous dSMN. The considerable degree of rescue
achieved with such low expression levels shows that dSMN is
made in greater quantities than required by the fly. Similar obser-
vations have been made in mammalian cell lines, wherein the
phenotypic effects of SMN reduction are observed only when
SMN levels are reduced by 85%–95% (Zhang et al., 2008; Bo-
werman et al., 2012). Interestingly, we found that expression of
the WT transgene with an Actin5C promoter failed to rescue
the null mutant beyond pupal stages, despite the fact that this
construct expressed much higher levels of dSMN protein than
the native promoter driven construct (Figure 3D). These results
suggest that the Actin5C promoter fails to express dSMN in
some critical tissue or developmental window.
Transgenic Expression of SmnT205I Rescues Larval
Locomotion
Consistent with previous reports (Chan et al., 2003; Shpargel
et al., 2009), we found that Smn/ animals display significant
defects in larval locomotion. To further characterize these loco-
motor defects, we employed two previously described assays
(Wu et al., 2003; Ubhi et al., 2007). In the ‘‘righting’’ assay,
each larva was placed on its dorsal surface, and the time taken
to return to its ventral surface (the crawling position) was
measured (Figure 3E). The Smn/ larvae took a significantly
longer time to return to the crawling position compared to OR.
Larval motility was rescued in animals carrying the WT trans-
gene, and to a large extent in the T205I transgenic animals,
which showed a relatively mild defect. In the ‘‘burrowing’’ assay,
30 larvae were placed atop a dish containing 1.5% agar/
molasses media and incubated at room temperature in the
dark. After 2 hr, the number of larvae remaining on top of the
medium was recorded. The assay was repeated three times
per genotype. We found that the Smn/mutants do not burrow628 Cell Reports 1, 624–631, June 28, 2012 ª2012 The Authorsinto the medium at all (Figure 3F). However, we also noticed that
if there were surface defects (cuts) present in the media, some of
these larvae worked themselves into the crevices. Importantly,
the burrowing behavior was restored in both the WT and T205I
transgenic animals (Figure 3F). We conclude that SmnT205I
rescues the larval viability and locomotor defects observed in
the null mutants.
SmnT205I and SmnWT Transgenic Larvae Are Functional
in snRNP Biogenesis
Phenotypically, the SmnT205I flies more closely resemble SmnWT
animals than they do the Smn null mutants. To determine the
degree to which this resemblance extends to themolecular level,
we quantified the snRNAs in Smn/, SmnWT, and SmnT205I
animals. Larvae from each of the three aforementioned geno-
types, along with OR, were harvested just prior to the beginning
of the lethal phase (i.e., at 76 hr) and snRNA levels were
analyzed by northern blotting (Figure 4A). As noted earlier, U1,
U4, U5, U11, U12, and U4atac snRNAs showed a reduction in
the null animals (Figure 4B). Again, U12 and U4atac levels
were the most severely affected (60% reduction). The SmnWT
and SmnT205I animals showed very similar snRNA profiles,
despite differences in adult viability. Both transgenes failed to
rescue U1, U4, and U4atac snRNA levels and only partially
rescued U12 and U5 snRNAs (Figure 4B). Thus, we conclude
that the SmnT205I mutant is functional in snRNP biogenesis. In
support of this interpretation, the human counterpart to this
mutation, SMNT274I, was shown to be active in a HeLa cell
Sm-core snRNP assembly assay (Shpargel and Matera, 2005).
We also analyzed minor-class intron splicing in the two
transgenic rescue lines. Among the four mRNAs that showed
slight, but significant, reductions in the Smn null mutant back-
ground (Figure 2), there was no correlation among the SmnWT
and SmnT205I samples (Figure S2). Two of the mRNAs
(CG18177 and CG15081) showed no significant differences
upon expression of either transgene. CG11839 mRNA was
restored to OR levels only by expression of SmnWT, whereas
CG33108 levels were restored only by expression of SmnT205I
(Figure S2).
SmnT205I Is a Good Model for Intermediate SMA
The human SMNT274I mutation was identified in patients with
milder forms of SMA, types II/III (Sun et al., 2005). These patients
show a later age of onset, decreased severity of symptoms, and
longer life expectancy than do type I patients (Ogino andWilson,
2004). The Drosophila equivalent of this mutation, SmnT205I,
recapitulates several key features of intermediate SMA,
including a slight deficiency in motor function and a much longer
lifespan than the null mutant. We also observed a mild defect in
oligomerization of dSMN(T205I), suggesting that on a molecular
level, this Drosophila protein behaves similarly to the human
mutation. We conclude that the SmnT205I flies represent a good
model for intermediate SMA.
SMN, snRNA Levels, and SMA
As shown above, transgenic expression of SmnWT was able to
rescue the locomotion and viability defects observed in Smn
null mutants; however, a majority of the snRNAs were largely
unrestored to wild-type levels. Given the considerable degree
of phenotypic rescue, this was an unexpected finding, suggest-
ing that the observed reduction in snRNAs in the null animals is
not a major contributor to larval locomotion and viability.
Consistent with our findings, previous studies using mouse
models of SMA have also reported decreases in snRNA levels,
particularly for U12 andU4atac (Gabanella et al., 2007;Workman
et al., 2009). Other investigators reportedwidespread pre-mRNA
splicing changes in both minor- and major-class introns in late-
symptomatic SMA mice (Zhang et al., 2008). However, subse-
quent studies revealed that these splicing defects are likely
a secondary consequence of severe SMN loss, as pre- and
early-symptomatic SMAmice did not show an enrichment of un-
spliced introns (Ba¨umer et al., 2009).
In our Drosophila system, we note that U12 and (to a lesser
extent) U5 levels were partially rescued by transgenic expres-
sion of SmnWT and SmnT205I, although U4atac levels remained
low (Figure 4B). Thus, one explanation for our results could be
that splicing of minor-class (U12-specific) introns is sensitive to
small changes in snRNA concentrations and that U12 and U5
are limiting factors, whereas U4atac is not. We tested this
hypothesis by using qRT-PCR to measure mRNA levels in 18
of the 20 predicted minor-class introns in the Drosophila tran-
scriptome (Lin et al., 2010). As shown in Figure 2, a hypomor-
phic mutation in the U6atac gene resulted in pronounced
defects in splicing of minor-class introns; however, splicing of
these same mRNAs was largely unaffected in Smn null mutants.
Among the minor-intron transcripts we analyzed, the steady-
state levels of two mRNAs, CG15081 (Phb2/Rea in mice) and
CG33108 (ortholog unknown), were reduced by roughly 50%
in Smn/ larvae. It is possible that reduction in levels of one
or more of these mRNAs could contribute to the phenotype
of Smn null mutants; however, CG15081 heterozygotes arecompletely viable (see Flybase). A similar decrease in levels
of the Phb2 mRNA in mice was shown to affect neither organ-
ismal viability nor motor function (Park et al., 2005), strongly
suggesting that haploinsufficiency for CG15081 is not the cause
of the Smn phenotype.
These observations question the significance of snRNA levels
in human SMA etiology. In this regard, it is important to note that
recessive point mutations in the gene encoding human U4atac
snRNA do not phenocopy SMA. Instead, loss of U4atac function
causes a disease known as microcephalic osteodysplastic
primordial dwarfism type I (MOPD I), which is characterized by
severe intrauterine growth retardation and multiple organ abnor-
malities (Edery et al., 2011; He et al., 2011). Similar to the fruitfly
U6atacmutants (Pessa et al., 2010; this work), cells derived from
MOPD I patients display marked defects in splicing of minor-
class introns, whereas splicing of major-class (U2-type) introns
is unaffected (Edery et al., 2011; He et al., 2011). Although we
cannot entirely exclude the possibility that tissue-specific
defects in minor-intron splicing may be causative for SMA, our
finding that transgenic expression of SmnWT can rescue viability
and fertility without restoring U4atac levels effectively uncouples
the observed global snRNA deficits from the organismal pheno-
type. Moreover, it is important to note that the Smn and U6atac
mutants were analyzed just prior to onset of the lethal phase. At
this time point, Smn null animals already display significant
motor function defects. We therefore conclude that perturba-
tions in minor spliceosome levels are not likely to be causative
for the larval locomotion and viability defects observed in Smn
null mutants.
With the possible exception of U5, SmnT205I animals have
nearly identical snRNA profiles to those of the SmnWT animals,
yet most of the T205I animals die as pupae. Given the interme-
diate phenotype of both humans and fruit flies expressing the
T274I/T205I mutation and the fact that human SMNT274I is active
in Sm-core assembly (Shpargel and Matera, 2005), these find-
ings strongly suggest that mutation of this residue disrupts
a second, essential function of SMN protein. This does not
mean that splicing plays no role in downstream SMA pathology;
it clearly does. There is strong evidence for a negative feedback
loop wherein low levels of SMN protein exacerbate exon skip-
ping of human SMN2, leading to a further reduction in SMN
expression (Jodelka et al., 2010; Ruggiu et al., 2012). However,
because Smn is a single-exon gene in Drosophila, our system
also uncouples protein-based defects in SMN from autologous
feedback regulation via splicing. In conclusion, our results
demonstrate that the reduction in snRNA levels observed in
Smn mutants is not a major contributor to organismal lethality
and indicate that non-snRNP biogenesis functions of SMN play
critical roles in the etiology of SMA. Molecular identification of
this second SMN function will be an important subject of future
investigation.EXPERIMENTAL PROCEDURES
Fly Stocks and Genetics
All stocks were cultured on molasses and agar at room temperature (24 ± 1C)
in half-pint bottles. Oregon-R was used as the wild-type allele. The SmnX7
microdeletion allele (Chang et al., 2008) was a gift from S. Artavanis-TsakonasCell Reports 1, 624–631, June 28, 2012 ª2012 The Authors 629
(Harvard University, Cambridge, MA, USA). The SmnD (f01109) transposon
insertion allele was obtained from the Exelixis collection at Harvard Medical
School and isogenized to remove non-Smn flies contaminating this stock (Ra-
jendra et al., 2007). WT and T205I transgene constructs were made using
a 3kb fragment encompassing the entire Smn coding region, cloned into
the pAttB vector (Bischof et al., 2007). A 3X FLAG tag was inserted down-
stream of the start codon. The constructs were injected into embryos by Best-
Gene Inc. (Chino Hills, CA, USA). To rescue the Smn null phenotype, the WT
and T205I transgenic lines were recombined with the SmnD line. Recombi-
nants were identified by genotyping, verified by western blotting for FLAG-
dSMN expression, and subsequently crossed with SmnX7 for analysis.
U6atack01105/CyO Dfm-Yfp flies were a gift from B. McCabe (Columbia Univer-
sity, New York City, NY, USA).
Antibodies and Western Blotting
Larval, pupal, and adult lysates were prepared by crushing the animals in
lysis buffer (50mM Tris-HCl [pH 7.5], 150 mM NaCl, 1mM EDTA, 1% NP-40)
with 1X protease inhibitor cocktail (Invitrogen, Carlsbad, CA, USA) and
clearing the lysate by centrifugation. Western analysis was performed using
standard protocols. Rabbit anti-dSMN serum was generated by injecting
rabbits with purified full-length dSMN protein (Pacific Immunology Corp.,
Ramona, CA, USA) and was subsequently affinity purified. For western blot-
ting, dilutions of 1 in 2,500 for the affinity purified anti-dSMN, 1 in 10,000 for
anti-a tubulin (Sigma-Aldrich, St. Louis, MO, USA), and 1 in 10,000 for
polyclonal anti-Myc (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were
used. Anti-FLAG antibody crosslinked to agarose beads (EZview Red Anti-
FLAG M2 affinity gel, Sigma-Aldrich) was used to immunoprecipitate FLAG-
tagged proteins.
Northern Blotting
Larvae, pupae, and adultDrosophilawere homogenized in TRIZOL (Invitrogen)
and total RNA was extracted following the manufacturer’s instructions. RNA
was run on a 10% polyacrylamide-urea gel (Invitrogen), transferred to a nylon
membrane, and probed with 32P-labeled PCR products corresponding to the
Drosophila melanogaster U1, U2, U4, U5, U6, U11, U12, U4atac, U6atac, and
7SK cDNAs. The blots were visualized using a Typhoon phosphorimager
(Molecular Dynamics, Sunnyvale, CA, USA), and quantification was performed
by densitometry using ImageQuant software.
Larval Motility Assays
Larvae used for the motility assays were 76 hr old. For the righting assay,
larvae were placed on a 3% agarose plate for 120 s to allow them to equilibrate
to the new environment. They were then placed on their dorsal surfaces, and
the time taken to return to a crawling position was noted. The assay was termi-
nated at 120 s. For the burrowing assay, 30 larvae were placed on a molasses
plate with 1.5% agarose. The plates were kept in the dark, and the number of
larvae remaining on the surface was counted after 2 hr. Statistical significance
for righting and burrowing assays was determined using Student’s t test and
chi-square analysis, respectively.
Real-Time PCR
One microgram of total RNA from 76 hr larvae was used in a 20 ml reverse
transcriptase reaction with random hexamer primers (Superscript III first
strand synthesis system, Invitrogen), and 50–100 ng of the cDNA was
used for qRT-PCR. Real-time PCR reactions were carried out on an Applied
Biosystems 7900HT Fast Real-time PCR machine using Maxima SYBR
Green/Rox qPCRmaster mix (Fermentas, Burlington, Ontario, Canada). Three
technical replicates were run for each reaction, and three biological replicates
were tested for each genotype. A 2-step PCR reaction was used, and the data
were analyzed using the DDCt method.
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